Health Care • Biotechnology: Pharmaceutical Preparations
$35.25 ▲ +0.48
(+1.38%)
MKT CAP: $4.16B • VOL: 5.72M
52W L $28 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$30
MEDIAN
$39
MEAN
$40
HIGH
$48
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INDV TAPE
INDV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $42.65 | $40.54 | 2025-02-14 | $32.08 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $44.41 | $41.59 | 2025-02-06 | $33.13 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $40.18 | $38.78 | 2025-01-29 | $33.84 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $35.95 | — | 2025-01-17 | $34.55 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $31.02 | $33.49 | 2025-01-09 | $31.37 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $41.95 | $36.66 | 2024-12-18 | $30.67 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $34.19 | $35.60 | 2024-12-04 | $32.78 | -4.3% | 48% | C |